Who can have Mounjaro, and does it apply to you?

What BMI do you actually need to qualify for Mounjaro?

The licensed threshold for Mounjaro in the UK is a BMI of 30 or above, used alongside a reduced-calorie diet and increased physical activity. That covers most adults classified as obese by standard UK definitions. If your BMI sits between 27 and 29.9 (the overweight range) you can still qualify, provided you have at least one weight-related health condition. The conditions recognised under the licence include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea and cardiovascular disease.

BMI thresholds are not fixed for every background. UK clinical guidance acknowledges that cardiometabolic risk rises at lower BMI for certain ethnic groups, and the standard thresholds are each reduced by 2.5 kg/m² as a result. For South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the qualifying BMI for Mounjaro without a comorbidity falls to 27.5, and the comorbidity route opens at 24.5. If you are unsure where you stand, the NHS BMI calculator is a useful starting check, though your prescriber will make the clinical call.

It is worth keeping in mind that Mounjaro is also licensed for type 2 diabetes management at the same doses, so people managing both conditions through treatment may qualify on that basis too. A prescriber will discuss which indication applies to you, and our page covering who can take Mounjaro sets out the full eligibility picture if you want to check the criteria in detail before your consultation.

Who is explicitly excluded from having Mounjaro?

Meeting the BMI criteria is necessary but not sufficient. Several situations mean Mounjaro is not appropriate, regardless of weight. The medicine is not licensed for anyone under 18. It is not recommended during pregnancy, and Novo Nordisk's and Lilly's guidance, alongside NHS advice, is clear that treatment should stop before trying to conceive; women should discuss contraception plans with their prescriber before starting, since the pill's absorption may be reduced during early treatment and after each dose increase.

There are medical histories that require particular caution or rule treatment out entirely. A personal or close family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) is a contraindication. A history of pancreatitis requires careful prescriber assessment. Certain gastrointestinal conditions, severe kidney or liver impairment, and some medicines combinations will also influence whether a prescription is appropriate. Our page on who cannot have Mounjaro goes into each exclusion in detail.

This is why the clinical consultation exists. The list of contraindications is specific, and the only person positioned to work through it properly is a qualified prescriber who has your full medical picture in front of them.

Does the NICE recommendation change who can get Mounjaro?

NICE published its appraisal of tirzepatide (Mounjaro) in December 2024 and updated it in September 2025. The NICE recommendation (TA1026) covers NHS prescribing specifically, and the thresholds it sets are stricter than the medicine's licence: BMI of 35 or above plus at least one weight-related comorbidity, within a structured NHS weight management pathway. NHS access is being phased in by cohort, and even people who meet the criteria may face waiting lists.

The licensed eligibility (BMI ≥30, or ≥27 with a comorbidity) is what governs private prescribing. At nume, our prescribers work to the licensed criteria, which means many people who do not yet meet the NHS thresholds, or who do not want to wait, can still access treatment privately following clinical assessment. You can explore how to get Mounjaro in the UK for a fuller breakdown of the NHS versus private routes.

One practical point: if a clinical trial showed less than 5% weight loss after six months at the highest tolerated dose, NICE recommends reviewing whether continuation makes sense. A similar principle applies in private practice, treatment should be working. Our prescribers discuss progress at every repeat order.

How does the clinical assessment at nume work in practice?

Filling in your health questionnaire online is step one. A GPhC-registered Independent Prescriber (a real clinician, not an automated system) reads your answers the same day. As part of that review, we verify your identity with photo ID and confirm your weight on a live video call. We also check your Summary Care Record where appropriate and, in line with GPhC guidance, notify your GP.

If you are transferring from another provider or requesting a dose increase, your prescriber will ask for evidence of your current treatment and progress before approving any change. It is a more thorough process than some people expect from an online pharmacy, and that is by design. You can read more about Mounjaro and who it's suitable for if you want to go deeper into the clinical nuances before your consultation. Our clinical team is available for aftercare questions seven days a week once treatment starts.

If you want to understand the wider context of what Mounjaro is and how it works before thinking about eligibility, the Mounjaro overview page covers the mechanism, the evidence and the treatment structure in full. For those who want to know what a Mounjaro prescription actually involves once approved, our guidance on accessing Mounjaro privately walks through the process from consultation to delivery. One transparent price covers the consultation, prescription, treatment and free next-working-day tracked delivery, no subscription, no hidden fees.

If you have read this and think you may qualify, the next step is a free consultation. Our prescribers will give you a clear answer based on your individual circumstances, not a generic eligibility checklist.

Start your free consultation and a prescriber will review your case the same day.